Levron Cardiovascular
Minimally Invasive Device for Heart Failure
Company Overview
Snapshot
Founded in June 2021 by Meir Kenigsztein, Dr. Shimon Eckhouse, and Prof. Amir Landesberg, Levron Cardiovascular operates with 1–10 employees. The company has secured funding across one round, with Shoni Health Ventures participating as a lead investor. In November 2025, Levron Medical exited stealth mode to advance its Cardio-Respiratory Physiology Assist (CRPA) technology for heart failure treatment.
Business overview
Levron Cardiovascular develops a novel autonomic integrated diagnostic and therapeutic minimally invasive device for cardiac failure patients. The company's technology integrates diagnosis and treatment, aiming to shift fluids from the lung and reduce cardiac workloads. It provides adaptive treatment for NYHA stage 3 heart failure, focusing on eliminating lung congestion. Levron Cardiovascular operates within the Health Tech & Life Sciences sector, specifically targeting the Medical Devices and Medical Treatment & Therapeutics markets.
Strategic signal
In November 2025, Levron Medical exited stealth mode to advance its Cardio-Respiratory Physiology Assist (CRPA) technology for heart failure treatment. This move signals a significant step towards commercialization and clinical validation, following positive first-in-human results. The collaboration with Sheba Medical Center for clinical trials and the backing from investors like Shoni Health Ventures indicate strong market validation and potential for transforming existing cardiac devices into smart assist platforms, which could significantly improve outcomes for heart failure patients.
Log in to access full profile ›Company Intelligence Q&A
- What is Levron Cardiovascular's core technology?
- Levron Cardiovascular is developing Cardio-Respiratory Physiology Assist (CRPA) technology, a novel autonomic integrated diagnostic and therapeutic minimally invasive device designed for heart failure patients.
- When did Levron Medical exit stealth mode?
- Levron Medical exited stealth mode in November 2025 to advance its Cardio-Respiratory Physiology Assist (CRPA) technology for heart failure treatment.
- Which investors participated in Levron Cardiovascular's funding round?
- In November 2025, Levron Cardiovascular secured funding from investors including.
- What is the primary application of Levron Cardiovascular's device?
- The device is intended for cardiac failure patients, integrating diagnosis and treatment to shift fluids from the lung and reduce cardiac workloads, providing adaptive treatment for NYHA stage 3 heart failure.
- What is the current product stage of Levron Cardiovascular's technology?
- Levron Cardiovascular's technology is currently in the clinical trial stage, with clinical validation set to begin at Sheba Medical Center following positive first-in-human results.